Search

Tradipitant

[L54903] Tradipitant has also been investigated in gastroparesis,COVID-19-induced pneumonia, and atopic dermatitis.[A275348, A275358, A275363] … [L54903] NK-1 receptors are expressed in the brainstem and nucleus tractus solitarius, which receives emetogenic signals from various stimuli including dizziness and vertigo.

Strontium chloride

SrCl2 is useful in reducing tooth sensitivity by forming a barrier over microscopic tubules in the dentin containing nerve endings that have become exposed by gum recession [A33167, A33168]. … Such strontium chloride toothpaste formulations may subsequently not be available for sale anymore in certain parts of the world [A33167, A33168].

Vibrio cholerae CVD 103-HgR strain live antigen

prevention to become available in the U.S. … [A244494] Vaxchora was later approved by the European Commission in April 2020.[L39729] It is indicated for individuals aged two years and older.[L12801]

Eletriptan

Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.

Calcium alginate

Dezocine

Dezocine is a partial opiate drug and is used for pain management. … Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea.

Gadopiclenol

It is indicated for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and the body. … [A254002,A254017] In September 2022, the use of gadopiclenol was approved by the FDA.

Pitolisant

FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults.[L8063] … [A32024] Pitolisant therapy was also effective in treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and increased the mean sleep onset latency.

Datopotamab deruxtecan

[L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623] … [L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer.

Mobocertinib

It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis ( … NSCLC in patients with _EGFR_ exon 20 insertion mutations who have failed previous therapies.